Business Context and Reporting Period
This Form 6-K filing by GSK plc (the "Company") reports a transaction in its own shares for the month of June 2025. The filing details a share repurchase executed on June 9, 2025, pursuant to an existing buyback programme and a non-discretionary agreement with Merrill Lynch International.
Key Financial Metrics
The filing focuses exclusively on capital allocation activities regarding share repurchases. It does not contain revenue, profit, cash flow, margin, debt, or liquidity metrics.
- Shares Purchased (June 9, 2025): 348,430 ordinary shares.
- Price Range: Lowest 1,503.50p; Highest 1,515.50p.
- Volume-Weighted Average Price (VWAP): 1,509.32p.
- Cumulative Purchases (Since June 4, 2025): 1,436,726 ordinary shares.
- Treasury Shares Held: 219,571,109 ordinary shares.
- Shares in Issue (Excluding Treasury): 4,095,711,802 ordinary shares.
- Treasury Voting Rights: 5.36% of total voting rights.
Material Changes
The filing reports a reduction in the number of shares in issue and an increase in treasury shares held by the Company. There are no material changes reported regarding operational performance, financial results, or debt levels as this is a transaction-specific disclosure.
Guidance, Outlook, and Risks
The filing contains no new financial guidance, outlook, or management commentary regarding business operations. It includes a standard cautionary statement noting that forward-looking statements are subject to risks and uncertainties, referencing the "Risk Factors" section in GSK's Annual Report on Form 20-F for 2024 and Q1 Results for 2025.
Investor Verification Checklist
- Verify the total remaining authorization under the existing buyback programme.
- Confirm the impact of the 5.36% treasury holding on voting rights calculations for major shareholders.
- Review the non-discretionary agreement terms announced on June 4, 2025, to understand the scope of future repurchases.
- Check the latest Form 20-F and Q1 2025 results for operational context not included in this transaction report.